GSA Capital Partners LLP Has $849,000 Stake in Savara Inc. $SVRA

GSA Capital Partners LLP lessened its stake in shares of Savara Inc. (NASDAQ:SVRA) by 62.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 140,753 shares of the company’s stock after selling 231,696 shares during the period. GSA Capital Partners LLP owned 0.07% of Savara worth $849,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. ProShare Advisors LLC lifted its position in shares of Savara by 35.5% during the 4th quarter. ProShare Advisors LLC now owns 34,869 shares of the company’s stock valued at $210,000 after acquiring an additional 9,133 shares during the period. Nan Fung Trinity HK Ltd. acquired a new position in shares of Savara during the 4th quarter valued at $10,182,000. F m Investments LLC lifted its position in shares of Savara by 56.5% during the 4th quarter. F m Investments LLC now owns 678,813 shares of the company’s stock valued at $4,093,000 after acquiring an additional 245,100 shares during the period. Swedbank AB lifted its position in shares of Savara by 54.5% during the 4th quarter. Swedbank AB now owns 850,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 300,000 shares during the period. Finally, Strs Ohio acquired a new position in shares of Savara during the 4th quarter valued at $160,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Performance

Shares of SVRA stock opened at $5.02 on Friday. The firm has a market capitalization of $1.03 billion, a PE ratio of -8.96 and a beta of 0.28. The firm has a fifty day simple moving average of $5.30 and a two-hundred day simple moving average of $5.50. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. Savara Inc. has a 12 month low of $1.89 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Analysts forecast that Savara Inc. will post -0.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SVRA shares. Oppenheimer started coverage on shares of Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 target price on the stock. William Blair set a $10.00 target price on shares of Savara in a research report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Savara in a research report on Monday, March 16th. Finally, Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.13.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.